- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02638493
The Compartmental Biology of HIV in the Male Genital Tract
IGHID 11526 - The Compartmental Biology of HIV in the Male Genital Tract
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
8 HIV positive men taking TDF/FTC and 8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis will provide multiple semen and blood samples during a 48-hour inpatient visit. 8 HIV positive men taking TAF (tenofovir alafenamide) will provide multiple semen and blood samples during a 48-hour inpatient visit.
Participants will take part in the study for approximately two months. After the screening visit, there is one 2 day overnight visit for intensive PK/PD (pharmacokinetic/pharmacodynamic) sampling. The investigators will study drug concentrations and intracellular endogenous nucleotide concentrations (dATP and dCTP) in seminal plasma and (where appropriate) seminal cells.
Samples will be analyzed through the use of novel laboratory methods to determine the seminal plasma and seminal cell concentrations of tenofovir and emtricitabine. New technologies will be used to better understand compartmental and intracellular antiretroviral pharmacology of nucleoside/tide reverse transcriptase inhibitors. Pharmacokinetic modeling will be used to estimate the primary outcomes.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
North Carolina
-
Chapel Hill, North Carolina, Yhdysvallat, 27599
- University of North Carolina
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Born male between the ages of 18 and 60
- HIV positive taking TDF/FTC (and a third drug) as treatment; or HIV negative men receiving TDF/FTC as pre-exposure prophylaxis; HIV positive men taking tenofovir alafenamide
- if on routine treatment must have been taking medication for at least 3 months and adherence to medication as assessed by blood plasma HIV RNA less than 50 copies per mL.
- documentation of at least 80% adherence to antiretroviral (ART) regimen, through clinician or self-report, with no missed doses in the 3 days prior to the inpatient visit.
- willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease that would pose unnecessary risk or interfere with study results.
- unwilling or unable to abstain from sexual activity 72 hours prior to overnight sampling visit
- unlikely to remain on current drug regimen during study period
- anemia that precludes blood donation
- unable to provide semen specimen
- current receipt of other medications that may affect endogenous nucleotide concentrations, such as additional HIV nucleoside reverse transcriptase inhibitors, ribavirin, or adefovir
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: Case-Control
- Aikanäkymät: Tulevaisuuden
Kohortit ja interventiot
Ryhmä/Kohortti |
---|
HIV positive TDF/FTC
8 HIV positive men taking TDF/FTC as treatment
|
HIV negative
8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
|
HIV Positive TAF
8 HIV positive men taking TAF as treatment
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Semen Clearance (CL) of Tenofovir
Aikaikkuna: Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Samples will be analyzed for drug concentrations at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 300mg dose of tenofovir.
|
Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Semen Clearance (CL) of Emtricitabine
Aikaikkuna: Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 200mg dose of emtricitabine.
|
Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Semen Clearance (CL) of Tenofovir Diphosphate
Aikaikkuna: Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from seminal mononuclear cells, following a 300mg dose of tenofovir.
|
Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Semen Clearance (CL) of Emtricitabine Triphosphate
Aikaikkuna: Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from seminal mononuclear cells, following a 200mg dose of emtricitabine.
|
Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Tenofovir Diphosphate
Aikaikkuna: Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from peripheral blood mononuclear cells, following a 300mg dose of tenofovir.
|
Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Emtricitabine Triphosphate
Aikaikkuna: Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from peripheral blood mononuclear cells, following a 200mg dose of emtricitabine.
|
Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Tenofovir Diphosphate (TFVdp)/Deoxyadenosine Triphosphate (dATP) Ratio in Seminal Mononuclear Cells
Aikaikkuna: Average concentration in a 24 hour dosing interval
|
dATP concentrations in seminal mononuclear cells will be measured and compared to tenofovir diphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects.
As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.
|
Average concentration in a 24 hour dosing interval
|
Emtricitabine Triphosphate (FTCtp)/Deoxyadenosine Triphosphate (dCTP) Ratio in Seminal Mononuclear Cells
Aikaikkuna: Average concentration in a 24 hour dosing interval
|
dCTP concentrations in seminal mononuclear cells will be measured and compared to emtricitabine triphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects.
As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.
|
Average concentration in a 24 hour dosing interval
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Päätutkija: Julie Dumond, PharmD, MS, University Of North Carolina, Chapel Hill
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004 Jan;2(1):33-42. doi: 10.1038/nrmicro794.
- Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007 Apr 17;146(8):591-601. doi: 10.7326/0003-4819-146-8-200704170-00010.
- Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. Targeting Trojan Horse leukocytes for HIV prevention. AIDS. 2010 Jan 16;24(2):163-87. doi: 10.1097/QAD.0b013e32833424c8. No abstract available.
- Joseph SB, Swanstrom R, Kashuba AD, Cohen MS. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol. 2015 Jul;13(7):414-25. doi: 10.1038/nrmicro3471. Epub 2015 Jun 8.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 15-2767
- R01DK108424-01 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Ihmisen immuunikatovirus
-
Oslo University HospitalValmis
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Allergy and Infectious Diseases (NIAID)ValmisHIV-infektiot | Taudin leviäminen, pystysuora | Vertical Human Immunodeficiency Virus TransmissionYhdysvallat, Etelä-Afrikka, Argentiina, Brasilia, Puerto Rico
-
Janssen-Cilag International NVValmisIhmisen immuunikatovirus (HIV) -infektiot | Acquired Immunodeficiency Syndrome (AIDS) -virusRanska, Yhdistynyt kuningaskunta, Belgia, Saksa, Espanja, Sveitsi, Tanska, Israel, Itävalta, Puola, Unkari, Ruotsi, Irlanti
-
IMMUNOe Research CentersValmisCVI - Common Variable ImmunodeficiencyYhdysvallat
-
Novartis PharmaceuticalsValmisCommon Variable Immunodeficiency (CVID), APDS / PASLISaksa, Venäjän federaatio, Irlanti, Italia, Yhdistynyt kuningaskunta, Valko-Venäjä, Alankomaat, Tšekki, Yhdysvallat
-
University of California, Los AngelesJeffrey Modell FoundationTuntematonCVI - Common Variable ImmunodeficiencyYhdysvallat
-
Michael HoelscherUniversity of Liverpool; National Institute for Medical Research (NIMR)... ja muut yhteistyökumppanitEi vielä rekrytointiaVauva, vastasyntynyt, sairaudet | Lapsen kuolema | Vauvan sairastuvuus | Vertical Human Immunodeficiency Virus Transmission | Lasten HIV-infektioMosambik, Tansania
-
University of MiamiJackson Health SystemEi ole enää käytettävissä
-
U.S. Army Medical Research and Development CommandValmis
-
Provention Bio, Inc.ValmisVirus; Infektio, Coxsackie (virus)Suomi